| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
The Journal of Immunology, Vol 152, Issue 10 5050-5059, Copyright © 1994 by American Association of Immunologists
ARTICLES |
H Jiang, D Burdick, CG Glabe, CW Cotman and AJ Tenner
Department of Molecular Biology and Biochemistry, University of California, Irvine 92717.
beta-amyloid peptides that accumulate within the brain of individuals with Alzheimer's disease bind to C1q and activate the classical C pathway via a specific interaction with a site within the collagen-like domain of C1q (C1q-CLF). Synthetic analogues of beta-amyloid peptides, beta 1-42 and beta 1-40, bound to C1q and were strong activators of C as assessed by both total C consumption and C4 consumption. beta 1-42 was significantly more effective than beta 1-40 in binding to C1q and triggering C activation, whereas beta 1-28 demonstrated little or no binding or C activation. This C-activating capacity seems to be largely correlated with the assembly of the beta 1-42 into low speed sedimentable aggregates and/or macromolecular fibrils. Radiolabeled C1q and C1q-CLF bind specifically to these aggregates or amyloid fibrils. In addition, using synthetic C1q peptides in a solid phase binding assay, the major binding site of beta 1-42 to C1q was localized to the C1q A chain collagen-like residues 14-26, a region previously described as a novel interaction site for Ab-independent activators of C1. C1q A chain peptide 14-26 blocked the ability of beta-amyloid peptides to activate the classical C pathway, providing evidence that this relatively unrecognized mechanism of C activation (via binding to the C1q-CLF) may have crucial physiologic consequences. Finally, these observations provide further support for the hypothesis that C activation and inflammation may be a component in the pathogenesis of AD and suggest possibilities for modulating the progression of AD.
This article has been cited by other articles:
|
|
 |
|
  E. Herczenik and M. F. B. G. Gebbink Molecular and cellular aspects of protein misfolding and disease FASEB J, July 1, 2008; 22(7): 2115 - 2133. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Kraus, G. S. Elliott, H. Chute, T. Horan, K. H. Pfenninger, S. D. Sanford, S. Foster, S. Scully, A. A. Welcher, and V. M. Holers CSMD1 Is a Novel Multiple Domain Complement-Regulatory Protein Highly Expressed in the Central Nervous System and Epithelial Tissues J. Immunol., April 1, 2006; 176(7): 4419 - 4430. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Osada, T. Hashimoto, A. Nishimura, Y. Matsuo, T. Wakabayashi, and T. Iwatsubo CLAC Binds to Amyloid {beta} Peptides through the Positively Charged Amino Acid Cluster within the Collagenous Domain 1 and Inhibits Formation of Amyloid Fibrils J. Biol. Chem., March 4, 2005; 280(9): 8596 - 8605. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. I. Fonseca, J. Zhou, M. Botto, and A. J. Tenner Absence of C1q Leads to Less Neuropathology in Transgenic Mouse Models of Alzheimer's Disease J. Neurosci., July 21, 2004; 24(29): 6457 - 6465. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
U. Kishore, S. K. Gupta, M. V. Perdikoulis, M. S. Kojouharova, B. C. Urban, and K. B. M. Reid Modular Organization of the Carboxyl-Terminal, Globular Head Region of Human C1q A, B, and C Chains J. Immunol., July 15, 2003; 171(2): 812 - 820. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Z.-Q. Xiong, W. Qian, K. Suzuki, and J. O. McNamara Formation of Complement Membrane Attack Complex in Mammalian Cerebral Cortex Evokes Seizures and Neurodegeneration J. Neurosci., February 1, 2003; 23(3): 955 - 960. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Rostagno, T. Revesz, T. Lashley, Y. Tomidokoro, L. Magnotti, H. Braendgaard, G. Plant, M. Bojsen-Moller, J. Holton, B. Frangione, et al. Complement Activation in Chromosome 13 Dementias. SIMILARITIES WITH ALZHEIMER'S DISEASE J. Biol. Chem., December 13, 2002; 277(51): 49782 - 49790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Wyss-Coray, F. Yan, A. H.-T. Lin, J. D. Lambris, J. J. Alexander, R. J. Quigg, and E. Masliah Prominent neurodegeneration and increased plaque formation in complement-inhibited Alzheimer's mice PNAS, August 6, 2002; 99(16): 10837 - 10842. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Tacnet-Delorme, S. Chevallier, and G. J. Arlaud {beta}-Amyloid Fibrils Activate the C1 Complex of Complement Under Physiological Conditions: Evidence for a Binding Site for A{beta} on the C1q Globular Regions J. Immunol., December 1, 2001; 167(11): 6374 - 6381. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. D. Webster, M. D. Galvan, E. Ferran, W. Garzon-Rodriguez, C. G. Glabe, and A. J. Tenner Antibody-Mediated Phagocytosis of the Amyloid {{beta}}-Peptide in Microglia Is Differentially Modulated by C1q J. Immunol., June 15, 2001; 166(12): 7496 - 7503. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. McGeer and E. G. McGeer Autotoxicity and Alzheimer Disease Arch Neurol, June 1, 2000; 57(6): 789 - 790. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Honda, F. Itoh, M. Yoshimoto, S. Ohno, Y. Hinoda, and K. Imai Association Between Complement Regulatory Protein Factor H and AM34 Antigen, Detected in Senile Plaques J. Gerontol. A Biol. Sci. Med. Sci., May 1, 2000; 55(5): 265M - 269. [Abstract] [Full Text]
|
|
|
|
 |
|
 S. E. Stoltzner, T. J. Grenfell, C. Mori, K. E. Wisniewski, T. M. Wisniewski, D. J. Selkoe, and C. A. Lemere Temporal Accrual of Complement Proteins in Amyloid Plaques in Down’s Syndrome with Alzheimer’s Disease Am. J. Pathol., February 1, 2000; 156(2): 489 - 499. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
I. Blasko, F. Marx, E. Steiner, T. Hartmann, and B. Grubeck-loebenstein TNF{alpha} plus IFN{gamma} induce the production of Alzheimer ß-amyloid peptides and decrease the secretion of APPs FASEB J, January 1, 1999; 13(1): 63 - 68. [Abstract] [Full Text]
|
|
|
|
 |
|
 B. M. Bradt, W. P. Kolb, and N. R. Cooper Complement-dependent Proinflammatory Properties of the Alzheimer's Disease beta -Peptide J. Exp. Med., August 3, 1998; 188(3): 431 - 438. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. C. Makrides Therapeutic Inhibition of the Complement System Pharmacol. Rev., March 1, 1998; 50(1): 59 - 88. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. R. Nepomuceno and A. J. Tenner C1qRP, the C1q Receptor That Enhances Phagocytosis, Is Detected Specifically in Human Cells of Myeloid Lineage, Endothelial Cells, and Platelets J. Immunol., February 15, 1998; 160(4): 1929 - 1935. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Kato, A. Fukunari, Y. Sakai, and T. Nakajima Prevention of Amyloid-Like Deposition by a Selective Prolyl Endopeptidase Inhibitor, Y-29794, in Senescence-Accelerated Mouse J. Pharmacol. Exp. Ther., October 1, 1997; 283(1): 328 - 335. [Abstract] [Full Text]
|
|
|
|
|
|
M. I. Brazil, H. Chung, and F. R. Maxfield Effects of Incorporation of Immunoglobulin G and Complement Component C1q on Uptake and Degradation of Alzheimer's Disease Amyloid Fibrils by Microglia J. Biol. Chem., May 26, 2000; 275(22): 16941 - 16947. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
